Table 1.
Table of basic characteristics
| Randomized controlled study | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Year | Country | Sample size | Gender(M/F) | Mean age(years) | TNM stage | Types | Dose | Combination Therapy | PD-L1 positive | Metastatic site |
| Liu | 2024 | China |
T:100 P:50 |
115/35 |
T:47 P:46.5 |
III-IVA | Locally advanced | 240mg | chemoradiotherapy |
T:72 P:34 |
NR |
| Mai | 2023 | China |
T:146 P:143 |
240/49 |
T:46 P:51 |
NR | Recurrent/Metastatic | 240mg | Chemotherapy |
T:109 P:109 |
Liver, bone, lungs |
| Single arm study | |||||||||||
| Study | Year | Country | Sample size | Gender(M/F) | Mean age(years) | TNM stage | Types | 240mg | Combination Therapy | PD-L1 positive | Metastatic site |
| Cao | 2024 | China | 23 | 15/8 | 52 | II-IVA | Locally advanced | 240mg | Chemotherapy | NR | NR |
| Chen | 2023 | China | 22 | 15/7 | 54.5 | NR | Recurrent/Metastatic | 240mg | chemoradiotherapy | NR | Liver, bone, lungs |
| Hua | 2021 | China | 25 | 18/7 | 49 | II-IVA | Recurrent/Metastatic | 240mg | radiotherapy | NR | NR |
| Wang | 2021 | China | 190 | 158/32 | 46.4 | III-IVB | Recurrent/Metastatic | 3mg/kg | chemoradiotherapy | 48 | NR |
| You | 2022 | China | 41 | 30/11 | 46 | NR | Recurrent/Metastatic | 240mg | Chemotherapy + VEGFR | NR | Liver, bone, lungs |
| Zhang | 2024 | China | 40 | 34/6 | 46 | NR | Recurrent/Metastatic | 240mg | Chemotherapy + VEGFR | NR | Liver, bone, lungs |
| Zou | 2024 | China | 21 | 15/6 | 55 | NR | Recurrent/Metastatic | 240mg | Chemotherapy | NR | Liver, bone, lungs |
M/F male/female, NR not reported, VGFR anti-vascular endothelial growth factor